Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Colorectal cancer
Bevacizumab + FOLFOXIRI (VEGF blockade + triplet chemo) misses PFS bar vs bevacizumab doublets in right-sided mCRC
Bevacizumab (anti-VEGF antibody) plus FOLFOXIRI (5-FU/leucovorin, oxaliplatin, irinotecan) was tested against bevacizumab plus investigator’s choice FOLFOX/FOLFIRI as first-line therapy in the randomized, open-label…
NCT03641976 - Trial result
Colorectal cancer
AtezoTRIBE: ctDNA (ctF) non-responders show larger PFS gain with PD-L1 atezolizumab add-on in 1L mCRC
In the Phase 2 AtezoTRIBE trial (NCT03721653), adding the PD-L1 inhibitor atezolizumab to first-line FOLFOXIRI/bevacizumab in untreated metastatic colorectal cancer was evaluated here with a translational…
NCT03721653 - Trial result
Colorectal cancer
Nivolumab+ipilimumab (PD-1+CTLA-4) PFS benefit holds with single MSI PCR or MMR IHC CDx in MSI-H/dMMR mCRC
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) was evaluated in a post hoc CheckMate-8HW (Phase 3; NCT04008030) analysis asking whether central companion diagnostics (Idylla MSI PCR and/or Dako MMR…
NCT04008030 - Trial result
Colorectal cancer
Panitumumab (EGFR mAb) maintenance benefit holds regardless of baseline dNLR in RAS-WT mCRC—dNLR mainly prognostic for OS
Baseline derived neutrophil-to-lymphocyte ratio (dNLR; cut-off 2.2) was assessed post hoc in the PANAMA/AIO KRK0212 randomized Phase 2 trial (NCT01991873) of first-line RAS WT mCRC receiving FU/FA ± panitumumab…
NCT01991873 - Trial result
Colorectal cancer
Panitumumab (EGFR mAb) drives ctDNA “High→Low” conversions that track ~51–61mo OS in 1L mCRC
ctDNA dynamics were analyzed in PARADIGM (Phase 3; mFOLFOX6 + panitumumab vs mFOLFOX6 + bevacizumab) using paired baseline and post-treatment plasma from 556 patients with mCRC, stratified into High/Mid/Low ctDNA by…
NCT02394795 - Trial result
Colorectal cancer
Zanzalintinib (multi-kinase TAM/MET/VEGFR inhibitor) + atezolizumab (PD-L1) shows OS/PFS benefit—and atezo exposure appears to matter—in refractory mCRC
Zanzalintinib (zanza) is an oral multi-kinase inhibitor (TYRO3/AXL/MER, MET, VEGFRs) combined with atezolizumab (atezo), an anti–PD-L1 antibody, in the Phase 3 STELLAR-303 trial in previously treated metastatic CRC…
- Trial result Spotlight
Stomach and esophageal cancer
Zanidatamab (dual HER2 bispecific; ECD2/4) + chemo in 1L HER2+ mGEA shows early ERBB2 ctDNA clearance tied to 12.5-mo mPFS
Zanidatamab is a dual HER2-targeted bispecific antibody (binding HER2 extracellular domains 2 and 4) evaluated with platinum/fluoropyrimidine chemotherapy (mFOLFOX6, CAPOX, or 5-FU/cisplatin) in a Phase 2, 1L HER2+…
NCT03929666 - Trial result Spotlight
Stomach and esophageal cancer
Durvalumab (PD-L1 blockade) + perioperative FLOT boosts EFS across completion strata in resectable G/GEJ cancer (MATTERHORN)
Durvalumab (anti–PD-L1 monoclonal antibody) was added to perioperative FLOT (5-FU/leucovorin/oxaliplatin/docetaxel) in MATTERHORN, a global, double-blind Phase 3 trial in untreated, resectable…
NCT04592913 - Trial result
Stomach and esophageal cancer
Tislelizumab (PD-1) + chemo adds ~2.6 months Q‑TWiST in peritoneal mets gastric/GEJ cancer
Tislelizumab (TIS), an anti–PD-1 monoclonal antibody engineered to reduce FcγR binding, was evaluated with fluoropyrimidine/platinum chemotherapy versus placebo (PBO) + chemotherapy in the global Phase 3,…
NCT03777657 - Trial result
Stomach and esophageal cancer
SHR-A1904 (garetatug rezetecan) CLDN18.2 ADC posts 25.5% ORR in heavily pretreated CLDN18.2+ solid tumors
SHR-A1904 is an investigational claudin-18.2 (CLDN18.2)–targeting antibody–drug conjugate evaluated in a global Phase 1/2a dose-escalation/optimization study in CLDN18.2-expressing relapsed/refractory solid tumors…
NCT05277168 - Trial result
Stomach and esophageal cancer
Avatrombopag (TPO-R agonist) sharply improves platelet recovery and “on-time” chemo delivery in persistent CIT (ACT‑GI)
ACT‑GI (NCT05772546) randomized patients with gastrointestinal malignancies and persistent chemotherapy‑induced thrombocytopenia (Plt <85×10^9/L on day 1 of a planned cycle) to avatrombopag 40mg PO daily vs placebo…
NCT05772546 - Trial result
Stomach and esophageal cancer
Zanidatamab (dual-HER2 bispecific) + PD-1 tislelizumab delivers OS gains regardless of PD-L1 in 1L HER2+ mGEA
Zanidatamab is a HER2-targeted bispecific antibody that binds two HER2 epitopes; in HERIZON-GEA-01 (Phase 3; NCT05152147), it was combined with platinum/fluoropyrimidine chemotherapy (CAPOX or FP) plus the anti–PD-1…
NCT05152147 - Trial result
Stomach and esophageal cancer
ONO-4578 (EP4 antagonist) + nivolumab + oxaliplatin/fluoropyrimidine extends PFS in 1L HER2-negative G/GEJ
ONO-4578 is an oral prostaglandin E2 (PGE2)–EP4 receptor antagonist intended to reverse myeloid-driven immunosuppression and potentially deepen anti–PD-1 benefit when added to nivolumab + chemotherapy. In the…
NCT06256328 - Trial result
Stomach and esophageal cancer
Pembrolizumab + Trastuzumab (PD-1/HER2) Sustains OS Gain in HER2+ G/GEJ Cancer
Pembrolizumab is a PD-1 inhibitor added to trastuzumab, an anti-HER2 antibody, plus platinum/fluoropyrimidine chemotherapy in the randomized Phase 3 KEYNOTE-811 first-line trial for untreated advanced/metastatic…
NCT03615326 - Trial result Spotlight
Bladder and urothelial cancer
Ave + SG (TROP2 ADC) extends PFS across visceral/liver/bone subgroups vs avelumab alone in 1L maintenance aUC
Avelumab is a PD-L1 inhibitor, and sacituzumab govitecan (SG) is a TROP2-directed ADC delivering SN-38; this randomized Phase 2 JAVELIN Bladder Medley trial (NCT05327530) tested Ave + SG vs avelumab monotherapy as 1L…
NCT05327530 - Trial result Spotlight
Bladder and urothelial cancer
LY4052031 (Nectin-4 topo1 ADC) delivers 48% ORR in metastatic urothelial cancer, including post-enfortumab activity
LY4052031 is a next-generation anti–Nectin-4 antibody-drug conjugate (ADC) with a cleavable linker and a novel topoisomerase I inhibitor payload (Camp98; DAR 8) evaluated in the NEXUS-01 Phase 1 dose-escalation study…
NCT06465069 - Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) delivers ~57% pCR and halves death risk in cisplatin-ineligible MIBC
Enfortumab vedotin (a Nectin-4–directed MMAE antibody–drug conjugate) plus pembrolizumab (anti–PD-1) was evaluated as perioperative (neoadj-adj) therapy in the Phase 3 KEYNOTE-905/EV-303 randomized trial…
NCT03924895 - Trial result Spotlight
Bladder and urothelial cancer
Erdafitinib (pan-FGFR inhibitor) delivers 55% CR chemoablation in FGFR3-mutant recurrent NMIBC
Oral erdafitinib, a pan-FGFR1–4 tyrosine kinase inhibitor approved in metastatic urothelial carcinoma, was tested as short “chemoablation” in a Phase II window-of-opportunity study before TURBT in recurrent…
NCT04917809 - Trial result
Bladder and urothelial cancer
Zelenectide pevedotin (BT8009) Nectin-4–targeted BDC + pembrolizumab hits 50% cORR and 13.0-mo mPFS in 1L cisplatin-ineligible la/mUC
Zelenectide pevedotin (zele; BT8009) is a Nectin-4–targeted Bicycle Drug Conjugate delivering MMAE (small 4.2 kDa construct with short plasma half-life), combined here with PD-1 blockade (pembrolizumab) in Duravelo-1…
NCT04561362 - Trial result
Bladder and urothelial cancer
Avelumab (PD-L1) 1L maintenance extends OS regardless of NECTIN4/HER2 RNA in la/mUC
Avelumab is an anti–PD-L1 monoclonal antibody used as first-line (1L) maintenance after platinum-based chemotherapy (PBC) in unresectable locally advanced/metastatic urothelial carcinoma (la/mUC). In the Phase 3…
NCT02603432 - Trial result
Bladder and urothelial cancer
Durvalumab (PD-L1) + tremelimumab (CTLA-4) neoadjuvant combo hits 44% pCR—but higher CTLA-4 dose triggers serious irAEs in cisplatin-ineligible MIBC
Durvalumab (anti–PD-L1) plus tremelimumab (anti–CTLA-4) was evaluated in a pilot neoadjuvant study for cisplatin-ineligible, high-risk muscle-invasive urothelial carcinoma (NCT02812420), with cystectomy planned 4–6…
NCT02812420 - Trial result
Bladder and urothelial cancer
Zelenectide pevedotin (BT8009) Nectin‑4 BDC + pembrolizumab delivers ~55–58% ORR in 1L la/mUC (Duravelo‑2 IA)
Zelenectide pevedotin (zele; BT8009) is a Nectin‑4–targeted Bicycle Drug Conjugate (BDC) evaluated with pembrolizumab in the Phase 2/3 Duravelo‑2 trial (NCT06225596; Cohort 1, previously untreated la/mUC; randomized…
NCT06225596 - Trial result
Bladder and urothelial cancer
LY4101174 (Nectin-4–targeted exatecan ADC) shows 18% ORR post-enfortumab vedotin in mUC—but with heavy hematologic toxicity
LY4101174 is a next-generation anti–Nectin-4 antibody-drug conjugate delivering the topoisomerase I inhibitor exatecan (DAR 8; maleimide–β-glucuronide poly-sarcosine linker) being evaluated in the EXCEED Phase 1…
NCT06238479 - Trial result
Bladder and urothelial cancer
Nogapendekin alfa inbakicept-pmln (IL‑15 superagonist) + BCG tops pembrolizumab (PD‑1) on 12‑mo CR in BCG‑unresponsive NMIBC CIS (MAIC)
Nogapendekin alfa inbakicept-pmln (NAI; an IL‑15 superagonist cytokine complex that expands/activates NK and CD8+ T cells) plus intravesical BCG from the Phase 3 QUILT‑3.032 trial (NCT03022825) was compared vs…
NCT03022825 - Trial result
Bladder and urothelial cancer
Durvalumab (PD-L1) + ddMVAC Hits ~49% pCR in Neoadjuvant MIBC; Tremelimumab (CTLA-4) Adds Toxicity
NEMIO (Phase I/II, randomized, noncomparative; NCT03549715) tested ddMVAC plus durvalumab with or without tremelimumab ahead of radical cystectomy in cisplatin-eligible cT2–T4a N0–1 muscle-invasive bladder cancer…
NCT03549715 - Trial result Spotlight
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) delivers ~50-month PFS and delays next intervention in grade 2 IDH-mutant glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2, evaluated in the global, randomized, double-blind Phase 3 INDIGO trial (NCT04164901) in residual/recurrent grade 2 IDH1/2-mutant…
NCT04164901 - Trial result
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) cuts seizure rates ~80% and delays QoL decline in INDIGO grade 2 glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2 evaluated vs placebo in the Phase 3 INDIGO trial (NCT04164901) in treatment-naïve (post-surgery only) grade 2 mIDH1/2 diffuse glioma…
NCT04164901 - Trial result
Brain and CNS tumors
NeoVax (personalized neoantigen long-peptide vaccine + poly-ICLC) plus PD-1 blockade (pembrolizumab) extends OS signals in newly diagnosed GBM
NeoVax is a personalized synthetic long-peptide neoantigen vaccine (up to 20 patient-specific peptides) formulated with the TLR3 agonist adjuvant poly-ICLC, designed to prime mutation-specific T cells; here it was…
NCT02287428 - Trial result
Brain and CNS tumors
DOC1021 (dubodencel) DC vaccine expands memory T cells with low tox in GBM chemoradiation combo
DOC1021 is an autologous dendritic-cell immunotherapy made by tandem loading patient DCs with autologous tumor mRNA plus tumor lysate to drive broad antigen presentation and a cDC1-like, CD8+ effector program; in a…
NCT04552886 - Trial result
Brain and CNS tumors
CART‑EGFR‑IL13Rα2 (EGFR/IL13Rα2 bivalent CAR‑T) shows 12.0‑mo mOS with no late safety signals in recurrent GBM
Eighteen patients with recurrent EGFR-amplified GBM received a single intracerebroventricular dose of CART‑EGFR‑IL13Rα2, an autologous bivalent CAR‑T designed to recognize EGFR (806 epitope) and IL13Rα2 (Phase 1, 3+3…
NCT05168423
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.